Immuron Limited Appendix 4E 30 June 2022 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2022 Name of entity: Immuron Limited ABN: 80 063 114 045 Year ended: 30 June 2022 Previous period: 30 June

Results for announcement to the market

No dividends have been paid or declared by the company for

the current financial year. No dividends were paid for the previous financial year.

Explanation of results

The reported after tax loss of $2,854,254 is after fully expensing

the company's research and development expenditure of $657,715 incurred during the year.

The company has engaged a specialised

R&D Tax consultant to review the research and development expenses of the company for the financial year 2022, to ensure the maximum

rebate is received under the Australian Government's R&D Tax Incentive program.

The gross revenue from contracts with

customers for the year was $765,193, which is an increase of 424.9% from the prior financial year (2021: $145,776), due to the easing

of travel restrictions from the Coronavirus (COVID-19) pandemic.

As at 30 June 2022 the company's

cash position was $22,110,278 (30 June 2021: $25,047,281). The company had trade and other receivables of $662,896 (30 June 2021: $334,707).

This receivables amount includes future receivables from the Australian Government under the R&D Tax Incentive program mentioned above.

The appendix 4E financial report follows,

with the further details to be included in the audited financial statements to be released by 30 September 2022.

Changes in controlled entities

There have been no changes in controlled entities during

the year ended 30 June 2022.

Other information required by Listing Rule 4.3A

The financial statements are currently in the process of being

audited. An audited financial statements along with the independent auditor report for the year end 30 June 2022 will be provided in the

INDEX TO CONSOLIDATED FINANCIAL

This page has been intentionally left blank.

Consolidated Statement of Profit or Loss and Other Comprehensive

For the year ended 30 June

The accompanying notes form part of these financial statements.

Consolidated Statement of Financial Position

The accompanying notes form part of these financial statements.

Consolidated Statement of Changes in Equity

For the year ended 30 June

The accompanying notes form part of these

financial statements.

Statement of Cash Flows

For the year ended 30 June

The accompanying notes form part of these financial

Consolidated Financial Statements

Significant Accounting Policies

The preliminary final report of Immuron Limited ("the

Company") for the financial year ended June 30, 2022 was authorized for issue in accordance with a resolution of the Directors on

Immuron Limited is a listed public company limited by shares

incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange ("ASX") and

The NASDAQ Capital Market ("NASDAQ").

The Group's principal activity

is oral immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the

treatment and prevention of a range of infectious diseases. Product sales comprise Travelan which is indicated to reduce the risk of contracting

travelers' diarrhea and Protectyn an OTC immune supplement for GI tract and liver health.

(a) Basis of preparation

These general purpose financial

statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting

Standards Board and the Corporations Act 2001. Immuron Limited is a for-profit entity for the purpose of preparing the financial

(i) Compliance with IFRS

The consolidated financial statements

of the Immuron Limited group also comply with International Financial Reporting Standards ("IFRS") as issued by the International

Accounting Standards Board ("IASB").

(ii) Historical cost convention

The financial statements have been prepared

on a historical cost basis.

(iii) Significant estimates and judgements

The group is in a position to meet

future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress

its research and development programs for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly,

the annual report does not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts

and classification of liabilities that might be necessary should the group not continue as a going concern.

Judgement has been exercised in

considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration

extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group

operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date sales has started to recover.

This note provides a list of the

significant accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already

been disclosed in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated.

The financial statements are for the group consisting of Immuron Limited and its subsidiaries.

(iv) New standards and interpretations not yet adopted

There are no standards that are

not yet effective and that would be expected to have a material impact on the Company in the current or future reporting years and on

foreseeable future transactions.

Summary of significant accounting policies

The following is a summary of the

material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently

applied, unless otherwise stated.

(b) Principles of consolidation

Subsidiaries are all entities (including

structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable

returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of

the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from

the date that control ceases.

The acquisition method of accounting

is used to account for business combinations by the group.